SCHEMBL20189716

SCHEMBL20189716

OCc1nc(NN=C(Br)C(F)(F)F)cnc1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 2/20 0.34
CYP1A2 P05177 1/20 0.34
CACNA2D1 P54289 1/20 0.34
TRPV3 Q8NET8 1/20 0.33
MERTK Q12866 1/20 0.33
MAPK1 P28482 1/20 0.33
CHRNA7 P36544 3/20 0.32
KDM1A O60341 1/20 0.32
MAOB P27338 1/20 0.32
GABBR2 O75899 1/20 0.32
GABBR1 Q9UBS5 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20189715 1.00 MALT1 (0.34) MALT1CYP1A2CACNA2D1TRPV3MERTK
SCHEMBL20189464 0.91 CYP1A2 (0.34) MALT1CYP1A2CACNA2D1MERTKCHRNA7
SCHEMBL20189463 0.91 CYP1A2 (0.34) MALT1CYP1A2CACNA2D1MERTKCHRNA7
SCHEMBL20190388 0.85 CACNA2D1 (0.37) CYP1A2CACNA2D1GABBR2GABBR1ADORA3
SCHEMBL20190386 0.85 CACNA2D1 (0.37) CYP1A2CACNA2D1GABBR2GABBR1ADORA3
SCHEMBL20189838 0.83 CYP1A2 (0.35) MALT1CYP1A2CACNA2D1TRPV3MERTK
SCHEMBL20189836 0.83 CYP1A2 (0.35) MALT1CYP1A2CACNA2D1TRPV3MERTK
SCHEMBL20189938 0.81 CYP1A2 (0.38) MALT1CYP1A2TRPV3CHRNA7KDM1A
SCHEMBL20189594 0.74 MALT1 (0.39) MALT1TRPV3CHRNA7KDM1AMAOB
SCHEMBL20190208 0.72 SCN10A (0.35) CYP1A2CACNA2D1MERTKCHRNA7GABBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2025-05-22 US disclosed
EP-4397308-A2 COMPOUNDS AND THEIR METHODS OFUSE Praxis Precision Medicines, Inc. (US) 2024-07-10 EP disclosed
EP-3548033-B1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2024-04-10 EP disclosed
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 US disclosed
US-11629146-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity PRAXIS PRECISION MEDICINES, INC. (US) 2023-04-18 US disclosed
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 US disclosed
EP-3548033-A1 COMPOUNDS AND THEIR METHODS OF USE Praxis Precision Medicines, Inc. (US) 2019-10-09 EP disclosed
WO-2018098499-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11629146-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity SCN1A, SCN5A, SCN3A MALT1 2748/4885CYP1A2 2190/4885CACNA2D1 103/4885
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B MALT1 2550/4885CYP1A2 1988/4885CACNA2D1 78/4885
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B MALT1 2550/4885CYP1A2 1988/4885CACNA2D1 78/4885
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B MALT1 2550/4885CYP1A2 1988/4885CACNA2D1 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.